CORT | NASDAQ
$121.46
$0.27 | 0.22%
TREND SIGNAL:
|2026-10-05
|2026-10-05
Company Overview:
Market Cap:
$12.77B
Trailing PE:
289.2x
FWD PE *:
30.4x
Payout Ratio (TTM):
—
52-Week Range:
$28.66 - $126.38
* Forward PE is based on street estimates.
10 Year CORT Performance Metrics:
Total Return (with DRIP):
1,822% (34.39% CAGR)
Total Return (no DRIP):
1,822% (34.39% CAGR)
Share Price:
1,822% (34.39% CAGR)
Yield on Cost (with DRIP):
—
Total Invested:
$10,000
Total Value (with DRIP):
$192,184
Total Return $ (with DRIP):
$182,184
CORT Total Return
1M
3M
6M
YTD
1Y
3Y
5Y
10Y
CORT Price Chart
1M
3M
6M
YTD
1Y
3Y
5Y
10Y
All
Unlock All Reports & Research Dividend Stocks like a BOSS!
Get 3 Months Free with Annual Plan
Get 3 Months Free with Annual Plan
PRO
$19/mo
$11.40/mo
7-day free trial
- Unlimited Portfolio Tracker
- Portfolio - Lots/Sales/Dividends
- Portfolio Auto-DRIP
- Buy/Sell Signals Dashboard
- Stock Fundamentals
- Compare Stocks Side-by-Side
- Revenue & EPS Estimates
- DCF Valuation Modeling
40% Lifetime Discount
Most Popular
PREMIUM
$32/mo
$19.20/mo
7-day free trial
- Everything in Pro
- YieldMax PNL Tracker
- YieldMax NAV Erosion Alerts
- YM ETFs Trend Signals
- 9/21 EMA Trend Signals
- Stocks Dashboard
40% Lifetime Discount
ULTRA
$64/mo
$38.40/mo
7-day free trial
- Everything in Premium
- 15min & 1hr Intraday Signals
- Group & weekly ETF estimates
- YouTuber Mode
- Trades summary + CSV export
- Priority data & support
40% Lifetime Discount
PRO
$171 ($14.25/mo)
$102.60/yr ($8.55/mo)
7-day free trial
- Unlimited Portfolio Tracker
- Portfolio - Lots/Sales/Dividends
- Portfolio Auto-DRIP
- Buy/Sell Signals Dashboard
- Stock Fundamentals
- Compare Stocks Side-by-Side
- Revenue & EPS Estimates
- DCF Valuation Modeling
Combined 55% Lifetime Discount
Most Popular
PREMIUM
$288 ($24/mo)
$172.80/yr ($14.40/mo)
7-day free trial
- Everything in Pro
- YieldMax PNL Tracker
- YieldMax NAV Erosion Alerts
- YM ETFs Trend Signals
- 9/21 EMA Trend Signals
- Stocks Dashboard
Combined 55% Lifetime Discount
ULTRA
$576 ($48/mo)
$345.60/yr ($28.80/mo)
7-day free trial
- Everything in Premium
- 15min & 1hr Intraday Signals
- Group & weekly ETF estimates
- YouTuber Mode
- Trades summary + CSV export
- Priority data & support
Combined 55% Lifetime Discount
CORT Financials: Earnings, Revenue, Cash Flow, Ebitda, Cash/Debt, Shares Float, etc:
CORT Revenue CAGR:1Y: 31.74%2Y: 25.05%5Y: 22.84%10Y: 29.23%
CORT EPS CAGR:1Y: 24.14%2Y: 6.07%5Y: 11.38%10Y: 45.44%
🔓 See the full chart40% off right now · 7-day free trial
CORT Net Income CAGR:1Y: 22.30%2Y: 10.06%5Y: 10.14%10Y: 46.00%
🔓 See the full chart40% off right now · 7-day free trial
CORT EBITDA CAGR:1Y: 31.10%2Y: 8.84%5Y: 5.22%10Y: 39.53%
🔓 See the full chart40% off right now · 7-day free trial
CORT Free Cash Flow CAGR:1Y: -29.32%2Y: -12.78%5Y: -6.85%10Y: 34.65%
🔓 See the full chart40% off right now · 7-day free trial
CORT Free Cash Flow / Share CAGR:1Y: -30.17%2Y: -13.72%5Y: -4.99%10Y: 35.23%
🔓 See the full chart40% off right now · 7-day free trial
CORT Operating Income CAGR:1Y: 54.83%2Y: 7.72%5Y: 5.27%10Y: 39.24%
🔓 See the full chart40% off right now · 7-day free trial
CORT Gross Profit CAGR:1Y: 31.98%2Y: 25.02%5Y: 0.00%10Y: 0.00%
🔓 See the full chart40% off right now · 7-day free trial
CORT Shares Outstanding CAGR:1Y: -1.74%2Y: 3.16%5Y: -1.35%10Y: 0.26%
🔓 See the full chart40% off right now · 7-day free trial
CORT Share Buybacks CAGR:1Y: -88.88%2Y: 81.50%5Y: -17.05%10Y: 0.00%
🔓 See the full chart40% off right now · 7-day free trial
CORT Stock-Based Comp CAGR:1Y: 54.63%2Y: 39.08%5Y: 21.59%10Y: 33.33%
🔓 See the full chart40% off right now · 7-day free trial
CORT Expenses CAGR:1Y: 4,335.09%2Y: 146.51%5Y: 84.27%10Y: 80.21%
🔓 See the full chart40% off right now · 7-day free trial
🔓 See the full chart40% off right now · 7-day free trial
🔓 See the full chart40% off right now · 7-day free trial
🔓 See the full chart40% off right now · 7-day free trial
🔓 See the full chart40% off right now · 7-day free trial
🔓 See the full chart40% off right now · 7-day free trial
Revenue, EPS, Net Income & Ebitda - Estimates VS Actual:
🔓 See the full chart40% off right now · 7-day free trial
CORT Actual Revenue CAGR:1Y: 31.74%2Y: 25.05%5Y: 22.84%10Y: 29.23%
🔓 See the full chart40% off right now · 7-day free trial
CORT Actual EPS CAGR:1Y: 24.14%2Y: 6.07%5Y: 11.38%10Y: 45.44%
🔓 See the full chart40% off right now · 7-day free trial
CORT Actual Net Income CAGR:1Y: 22.30%2Y: 10.06%5Y: 10.14%10Y: 46.00%
🔓 See the full chart40% off right now · 7-day free trial
CORT Actual EBITDA CAGR:1Y: 31.10%2Y: 8.84%5Y: 5.22%10Y: 39.53%
Ratios, Profit Margins & Return on Capital:
🔓 See the full chart40% off right now · 7-day free trial
CORT Net Profit Margin CAGR:1Y: -9.02%2Y: -12.87%5Y: -10.70%10Y: 12.76%
🔓 See the full chart40% off right now · 7-day free trial
CORT Gross Profit Margin CAGR:1Y: 0.18%2Y: -0.03%5Y: -0.02%10Y: 0.06%
🔓 See the full chart40% off right now · 7-day free trial
CORT Price to Earnings CAGR:1Y: -2.27%2Y: 51.32%5Y: 17.64%10Y: -9.88%
🔓 See the full chart40% off right now · 7-day free trial
CORT Price To Sales Ratio CAGR:1Y: -8.99%2Y: 31.88%5Y: 5.07%10Y: 1.62%
🔓 See the full chart40% off right now · 7-day free trial
CORT Return on Capital Employed CAGR:1Y: 38.43%2Y: -1.55%5Y: -1.65%10Y: -0.45%
🔓 See the full chart40% off right now · 7-day free trial
CORT Return on Invested Capital CAGR:1Y: 38.28%2Y: 6.45%5Y: 2.14%10Y: 6.49%
Projected Future Returns & Dividends for CORT
Based on past 10-year performance, here are CORT growth metrics:
Share price CAGR of +34.39%
Dividend CAGR of +0%
Using CORT CAGR metrics, we can estimate that your initial $10000 investment, over the next 10 years, should grow as follows:
| CORT (DRIP) | CORT - No DRIP | |
|---|---|---|
| Current Price | $121.46 | $121.46 |
| Start Shares | 82.33 | 82.33 |
| Start Value | $10,000 | $10,000 |
| After 10 years: | ||
| Final Share Count | 82.33 | 82.33 |
| Dividends Payment | $0.00 | $0.00 |
| Annual Dividends | $0 | $0 |
| Yield on cost | 0.00% | 0.00% |
| Share Price | $121.46 | $121.46 |
| Total Dividends | $0 | $0 |
| Final Value | $10,000 | $10,000 |
Estimated Future Value + Dividends - CORT
NOTE: Above numbers are our estimate based on CORT's Dividend and Price CAGR over past 10 years.
These numbers should only be considered as "potential future returns"! DRIP assumes reinvesting dividends; No-DRIP assumes collecting dividends as cash.
We cannot guarantee that your actual returns will meet these estimates.
Get the best Dividend Stock Research Tools:
Get 3 Months Free with Annual Plan
Get 3 Months Free with Annual Plan
PRO
$19/mo
$11.40/mo
7-day free trial
- Unlimited Portfolio Tracker
- Portfolio - Lots/Sales/Dividends
- Portfolio Auto-DRIP
- Buy/Sell Signals Dashboard
- Stock Fundamentals
- Compare Stocks Side-by-Side
- Revenue & EPS Estimates
- DCF Valuation Modeling
40% Lifetime Discount
Most Popular
PREMIUM
$32/mo
$19.20/mo
7-day free trial
- Everything in Pro
- YieldMax PNL Tracker
- YieldMax NAV Erosion Alerts
- YM ETFs Trend Signals
- 9/21 EMA Trend Signals
- Stocks Dashboard
40% Lifetime Discount
ULTRA
$64/mo
$38.40/mo
7-day free trial
- Everything in Premium
- 15min & 1hr Intraday Signals
- Group & weekly ETF estimates
- YouTuber Mode
- Trades summary + CSV export
- Priority data & support
40% Lifetime Discount
PRO
$171 ($14.25/mo)
$102.60/yr ($8.55/mo)
7-day free trial
- Unlimited Portfolio Tracker
- Portfolio - Lots/Sales/Dividends
- Portfolio Auto-DRIP
- Buy/Sell Signals Dashboard
- Stock Fundamentals
- Compare Stocks Side-by-Side
- Revenue & EPS Estimates
- DCF Valuation Modeling
Combined 55% Lifetime Discount
Most Popular
PREMIUM
$288 ($24/mo)
$172.80/yr ($14.40/mo)
7-day free trial
- Everything in Pro
- YieldMax PNL Tracker
- YieldMax NAV Erosion Alerts
- YM ETFs Trend Signals
- 9/21 EMA Trend Signals
- Stocks Dashboard
Combined 55% Lifetime Discount
ULTRA
$576 ($48/mo)
$345.60/yr ($28.80/mo)
7-day free trial
- Everything in Premium
- 15min & 1hr Intraday Signals
- Group & weekly ETF estimates
- YouTuber Mode
- Trades summary + CSV export
- Priority data & support
Combined 55% Lifetime Discount
Company Info
Corcept Therapeutics Incorporated (CORT) had its IPO on 2004-04-14, and is traded on NASDAQ stock exchange.
Corcept Therapeutics Incorporated, founded in 1998 and headquartered in Menlo Park, California, is a pharmaceutical firm dedicated to the discovery, development, and commercialization of treatments for serious metabolic, oncological, and neuropsychiatric disorders across the United States. Its primary commercial offering is Korlym (mifepristone) tablets, an oral medication taken once daily. Korlym is prescribed for adult patients diagnosed with endogenous Cushing's syndrome who suffer from hyperglycemia due to hypercortisolism, particularly those with type 2 diabetes or glucose intolerance, and for whom surgical options have either failed or are not viable. The company's development pipeline is robust, featuring relacorilant, which is being advanced for Cushing's syndrome. It is also investigating a combination of relacorilant with nab-paclitaxel; this pairing has concluded Phase II clinical trials for advanced ovarian tumors and is additionally being studied for conditions involving cortisol excess. Furthermore, Corcept is developing distinct selective cortisol modulators for specific indications such as metastatic castration-resistant prostate cancer and antipsychotic-induced weight gain, alongside research into FKBP5 gene expression assays.
CORT website: https://www.corcept.com
Get Full Access to All Reports with DRIPCalc PRO
Get 3 Months Free with Annual Plan
Get 3 Months Free with Annual Plan
PRO
$19/mo
$11.40/mo
7-day free trial
- Unlimited Portfolio Tracker
- Portfolio - Lots/Sales/Dividends
- Portfolio Auto-DRIP
- Buy/Sell Signals Dashboard
- Stock Fundamentals
- Compare Stocks Side-by-Side
- Revenue & EPS Estimates
- DCF Valuation Modeling
40% Lifetime Discount
Most Popular
PREMIUM
$32/mo
$19.20/mo
7-day free trial
- Everything in Pro
- YieldMax PNL Tracker
- YieldMax NAV Erosion Alerts
- YM ETFs Trend Signals
- 9/21 EMA Trend Signals
- Stocks Dashboard
40% Lifetime Discount
ULTRA
$64/mo
$38.40/mo
7-day free trial
- Everything in Premium
- 15min & 1hr Intraday Signals
- Group & weekly ETF estimates
- YouTuber Mode
- Trades summary + CSV export
- Priority data & support
40% Lifetime Discount
PRO
$171 ($14.25/mo)
$102.60/yr ($8.55/mo)
7-day free trial
- Unlimited Portfolio Tracker
- Portfolio - Lots/Sales/Dividends
- Portfolio Auto-DRIP
- Buy/Sell Signals Dashboard
- Stock Fundamentals
- Compare Stocks Side-by-Side
- Revenue & EPS Estimates
- DCF Valuation Modeling
Combined 55% Lifetime Discount
Most Popular
PREMIUM
$288 ($24/mo)
$172.80/yr ($14.40/mo)
7-day free trial
- Everything in Pro
- YieldMax PNL Tracker
- YieldMax NAV Erosion Alerts
- YM ETFs Trend Signals
- 9/21 EMA Trend Signals
- Stocks Dashboard
Combined 55% Lifetime Discount
ULTRA
$576 ($48/mo)
$345.60/yr ($28.80/mo)
7-day free trial
- Everything in Premium
- 15min & 1hr Intraday Signals
- Group & weekly ETF estimates
- YouTuber Mode
- Trades summary + CSV export
- Priority data & support
Combined 55% Lifetime Discount
Loading signals…
DCF Model — CORT
Value from:
🔒 Upgrade to unlock
The full DCF valuation — fair value, implied growth and the price path — is a paid feature.
Upgrade
Pay up to today
—
vs current price $121.46
—
Cash flow & implied price by year
FCF is negative or missing for this company (common for banks) — the model discounts EPS instead.
EPS is negative or missing for this company — Simple mode uses free cash flow per share instead.
Free cash flow today
—
grows for the next years
Then mature
—
every future dollar counted back to today
Pile of today-dollars
—
÷ shares
Implied price path
| Year | FCF | Implied price |
|---|
Sensitivity — fair value: growth ↓ × target return →
